BRPI0510260A - método para purificar um composto, e, kit farmacêutico - Google Patents

método para purificar um composto, e, kit farmacêutico

Info

Publication number
BRPI0510260A
BRPI0510260A BRPI0510260-0A BRPI0510260A BRPI0510260A BR PI0510260 A BRPI0510260 A BR PI0510260A BR PI0510260 A BRPI0510260 A BR PI0510260A BR PI0510260 A BRPI0510260 A BR PI0510260A
Authority
BR
Brazil
Prior art keywords
compound
purifying
pharmaceutical kit
formula
solvent
Prior art date
Application number
BRPI0510260-0A
Other languages
English (en)
Inventor
Bogdan Kazimierz Wilk
Arkadiy Zinoviy Rubezhov
Anthony Francis Hadfield
Jean Louise Helom
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0510260A publication Critical patent/BRPI0510260A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

MéTODO PARA PURIFICAR UM COMPOSTO, E KIT FARMACêUTICO. Métodos para purificar um composto da fórmula I são fornecidos, em que A, B, X, Q e R¬ 1¬ são aqui definidos. Os métodos incluem misturar o composto da fórmula I e um solvente; adicionar uma base ao solvente e precipitar o composto purificado da fórmula I.
BRPI0510260-0A 2004-04-27 2005-04-25 método para purificar um composto, e, kit farmacêutico BRPI0510260A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56565904P 2004-04-27 2004-04-27
PCT/US2005/013997 WO2005104711A2 (en) 2004-04-27 2005-04-25 Purification of progesterone receptor modulators

Publications (1)

Publication Number Publication Date
BRPI0510260A true BRPI0510260A (pt) 2007-10-23

Family

ID=34967887

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510260-0A BRPI0510260A (pt) 2004-04-27 2005-04-25 método para purificar um composto, e, kit farmacêutico

Country Status (9)

Country Link
US (3) US7514466B2 (pt)
EP (1) EP1756072A2 (pt)
JP (1) JP5039541B2 (pt)
CN (1) CN1953967B (pt)
AU (1) AU2005237520B2 (pt)
BR (1) BRPI0510260A (pt)
CA (1) CA2563063C (pt)
MX (1) MXPA06012403A (pt)
WO (1) WO2005104711A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
CN100522960C (zh) * 2004-04-08 2009-08-05 惠氏公司 作为黄体酮受体调节剂的硫代酰胺衍生物
MXPA06012402A (es) 2004-04-27 2007-01-17 Wyeth Corp Carbamato y tiocarbamato biarilos ciclicos que contienen cianopirrol y metodos para preparar los mismos.
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053595A1 (es) * 2005-04-28 2007-05-09 Wyeth Corp Forma purificada de tanaproget
US20060246128A1 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compositions containing same
CN101166736B (zh) 2005-04-28 2013-02-06 惠氏公司 他那普戈特的多晶型ⅱ
DE602006007453D1 (de) * 2005-04-28 2009-08-06 Wyeth Corp Zusammensetzungen mit mikronisiertem tanaproget
CN101166532B (zh) * 2005-04-28 2011-06-22 惠氏公司 微粒化的他那普戈特、组合物及其制备方法
PE20070220A1 (es) * 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
US20080319204A1 (en) * 2007-06-25 2008-12-25 Wyeth Process for the synthesis of progesterone receptor modulators
CA2710293A1 (en) 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
US20090197878A1 (en) * 2008-02-01 2009-08-06 Wyeth SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
NZ592275A (en) 2008-10-17 2013-04-26 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010045197A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
MY165579A (en) 2009-10-14 2018-04-05 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
CN105726531A (zh) 2010-02-26 2016-07-06 泽农医药公司 用于局部给药的螺-羟吲哚化合物的药物组合物及其作为治疗剂的用途
WO2016039750A1 (en) 2014-09-11 2016-03-17 Halliburton Energy Services, Inc. Cyanamide-based carbon dioxide and/or hydrogen sulfide scavengers and methods of use in subterranean operations
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
CN109369450B (zh) * 2018-10-31 2021-07-27 江苏省农用激素工程技术研究中心有限公司 三甲苯草酮的精制方法
EP4146626A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. CHEMOTHERAPEUTIC AGENTS BASED ON HETEROAROMATIC MACROCYCLIC ETHERS
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
JP2024537795A (ja) 2021-10-01 2024-10-16 ヌバレント， インク． ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS5168566A (en) * 1974-12-09 1976-06-14 Nippon Soda Co 4 * 5 * shianoimidazooru 5 * 4 * karubokishiamidono seiseihoho
DE2500092C3 (de) * 1975-01-03 1978-10-12 Bayer Ag, 5090 Leverkusen Verzweigte, hochmolekulare, thermoplastische und lösliche Polycarbonate
US4185009A (en) * 1975-01-03 1980-01-22 Bayer Aktiengesellschaft Branched, high-molecular weight thermoplastic polycarbonates
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4295987A (en) 1979-12-26 1981-10-20 The Procter & Gamble Company Cross-linked sodium polyacrylate absorbent
US5525727A (en) 1982-05-18 1996-06-11 University Of Florida Brain-specific drug delivery
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4829070A (en) 1982-05-18 1989-05-09 University Of Florida Novel redox carriers for brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
GB8714371D0 (en) * 1987-06-19 1987-07-22 Smith Kline French Lab Process
AU608891B2 (en) 1987-09-24 1991-04-18 Merck & Co., Inc. Solubility modulated drug delivery device
FR2635104B1 (fr) 1988-08-03 1992-04-30 Synthelabo Derives d'indolone, leur preparation et leur application en therapeutique
US5273752A (en) 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
KR0164842B1 (ko) 1990-03-24 1999-01-15 손정삼 신규 벤즈옥사진, 벤조티아진 유도체 및 그 제조방법
US5266325A (en) 1990-09-28 1993-11-30 Hydro Med Science Division Of National Patent Development Corp. Preparation of homogeneous hydrogel copolymers
AU651654B2 (en) 1992-01-14 1994-07-28 Endo Pharmaceuticals Solutions Inc. Manufacture of water-swellable hydrophilic articles and drug delivery devices
US5221791A (en) 1991-05-24 1993-06-22 Isp Investments Inc. Water-soluble biologically active ammonium salts
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5338846A (en) 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5854388A (en) 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
JPH07281374A (ja) 1994-04-12 1995-10-27 Konica Corp ハロゲン化銀カラー写真感光材料
JP3042894B2 (ja) 1995-07-07 2000-05-22 ファイザー製薬株式会社 サブスタンスｐアンタゴニストとしての置換ベンゾラクタム化合物
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5874430A (en) 1996-10-02 1999-02-23 Dupont Pharmaceuticals Company 4,4-disubstitued-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
FI971385A0 (fi) 1997-04-04 1997-04-04 Bioxid Oy Biokompatibel komposition, metoder foer dess framstaellning samt anvaendning daerav
US6015926A (en) 1997-05-16 2000-01-18 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
JPH1195372A (ja) 1997-09-24 1999-04-09 Konica Corp ハロゲン化銀カラー写真感光材料
FR2779429B1 (fr) 1998-06-03 2000-07-13 Synthelabo Derives d'oxindole, leurs preparations et leurs applications en therapeutique
US6048869A (en) * 1998-07-29 2000-04-11 Merck & Co., Inc. Tricyclic compounds
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
KR100732692B1 (ko) * 1999-05-04 2007-06-27 와이어쓰 프로게스테론 수용체 조절인자인 시클로티오카르바메이트유도체
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
JP2002543155A (ja) * 1999-05-04 2002-12-17 ワイス 抗プロゲスチン及びプロゲスチンを含有する避妊組成物
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
AU4813900A (en) * 1999-05-04 2000-11-17 American Home Products Corporation Contraceptive compositions containing indoline derivatives and progestational agents
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
JP2001031656A (ja) 1999-07-19 2001-02-06 Fuji Photo Film Co Ltd 複素環化合物の製造方法
JP2001168986A (ja) 1999-12-09 2001-06-22 Fujitsu Ltd 反復呼制御方法及びその方法を利用する交換機並びに反復呼制御プログラムを記録した記録媒体
AU2001228854A1 (en) * 2000-02-01 2001-08-14 Kyorin Pharmaceutical Co. Ltd. Alkali metal salt of thiazolidine-2,4-dione derivative
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US6716413B1 (en) 2000-10-16 2004-04-06 Mallinckrodt, Inc. Indole compounds as tissue-specific exogenous optical agents
WO2002102783A1 (en) 2001-06-19 2002-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
US7205407B2 (en) 2001-11-20 2007-04-17 Eli Lilly And Company 3-Substituted oxindole β3 agonists
EP1531824A4 (en) * 2002-06-25 2005-09-21 Wyeth Corp CYCLOTHIOCARBAMATIVE DERIVATIVES AS PR MODULATORS AND THEIR USE IN TREATING SKIN DISORDERS
WO2004000227A2 (en) * 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of skin disorders
AU2005237520B2 (en) * 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
US20070213526A1 (en) * 2006-03-07 2007-09-13 Wyeth Purification of progesterone receptor modulators

Also Published As

Publication number Publication date
AU2005237520B2 (en) 2012-01-19
US20130012702A1 (en) 2013-01-10
US20090143577A1 (en) 2009-06-04
MXPA06012403A (es) 2007-01-17
CA2563063C (en) 2014-06-03
JP2007534760A (ja) 2007-11-29
WO2005104711A3 (en) 2006-12-28
JP5039541B2 (ja) 2012-10-03
AU2005237520A1 (en) 2005-11-10
CA2563063A1 (en) 2005-11-10
EP1756072A2 (en) 2007-02-28
WO2005104711A2 (en) 2005-11-10
CN1953967A (zh) 2007-04-25
US8309594B2 (en) 2012-11-13
US8609712B2 (en) 2013-12-17
US7514466B2 (en) 2009-04-07
CN1953967B (zh) 2013-03-13
US20050250766A1 (en) 2005-11-10
WO2005104711A8 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
BRPI0510260A (pt) método para purificar um composto, e, kit farmacêutico
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BRPI0518647A2 (pt) processo para a produÇço de um composto, e, composto
BR0206433A (pt) Composto, composição farmacêutica, processo para a prepapação de um composto, e, uso de um composto
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
BRPI0418639A (pt) inibidores de dipeptidil peptidase
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
BRPI0516735B8 (pt) métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937)
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
BRPI0512310A (pt) compostos quìmicos
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
BRPI0508969A (pt) compostos orgánicos
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
DE602006019732D1 (de) Indolylmaleimidderivate
SE0401762D0 (sv) Novel compounds
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
DE602006017724D1 (de) Salicylsäurederivate
ATE449069T1 (de) Aminopropanolderivate
GEP20115243B (en) Novel camptothecin analogues compounds, a method for the preparation thereof and pharmaceutical compositions containing said compounds
EA200800235A1 (ru) Новые трициклические соединения, способ их получения и фармацевтические композиции, которые их содержат
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO.

B25D Requested change of name of applicant approved

Owner name: WYETH LLC. (US)

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]